Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. LCO
8. KR
9. MSTR
10. HOOD

Go back to Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'

Sarepta Therapeutics (SRPT) PT Raised to $70 at Piper Jaffray

March 2, 2018 7:02 AM EST

Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $70.00 (from $60.00) while maintaining a Overweight rating.

... More

Sarepta Therapeutics (SRPT) PT Raised to $79 at Leerink Partners

March 2, 2018 1:29 AM EST

Leerink Partners raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $79.00 (from $77.00) while maintaining a Outperform rating.

... More

Sarepta Therapeutics (SRPT) Tops Q4 EPS by 4c, Beats on Revenues

March 1, 2018 4:04 PM EST

Note: EPS may not be comparable

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.28), $0.04 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.48 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

... More